Eloxx Pharmaceuticals Free Cash Flow (FCF) History (ELOX)
Eloxx Pharmaceuticals reported −$31.9M in free cash flow for fiscal 2022, an increase of $3.2M from the previous fiscal year.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2022 | 2022-12-31 | −$31.9M | $3.2M | — | — |
| 2021 | 2021-12-31 | −$35.1M | $4.3M | — | — |
| 2019 | 2019-12-31 | −$39.4M | −$7.8M | — | — |
| 2018 | 2018-12-31 | −$31.6M | −$15.4M | — | — |
| 2017 · Dec 31 | 2017-12-31 | −$16.2M | −$14.2M | — | — |
| 2017 · Jun 30 | 2017-06-30 | −$1.9M | $1.7M | — | — |
| 2016 | 2016-06-30 | −$3.7M | $3.8M | — | — |
| 2015 | 2015-06-30 | −$7.5M | −$2.6M | — | — |
| 2014 | 2014-06-30 | −$4.9M | −$967,420 | — | −2673.19% |
| 2013 | 2013-06-30 | −$3.9M | $486,603 | — | −49928.47% |
| 2012 | 2012-06-30 | −$4.4M | $1.0M | — | −2195.25% |
| 2011 | 2011-06-30 | −$5.4M | −$649,223 | — | — |
| 2010 | 2010-06-30 | −$4.7M | — | — | −3388.75% |
Eloxx Pharmaceuticals quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2023 | 2023-09-30 | −$3.5M | $3.5M | — | — |
| Q2 2023 | 2023-06-30 | −$2.1M | $7.7M | — | — |
| Q1 2023 | 2023-03-31 | −$6.8M | $2.7M | — | — |
| Q4 2022 | 2022-12-31 | −$5.7M | $3.6M | — | — |
| Q3 2022 | 2022-09-30 | −$7.0M | $4.4M | — | — |
| Q2 2022 | 2022-06-30 | −$9.8M | −$130,000 | — | — |
| Q1 2022 | 2022-03-31 | −$9.5M | −$298,000 | — | — |
| Q4 2019 | 2019-12-31 | −$9.3M | −$95,000 | — | — |
| Q3 2019 | 2019-09-30 | −$11.3M | −$3.2M | — | — |
| Q2 2019 | 2019-06-30 | −$9.6M | −$1.1M | — | — |
| Q1 2019 | 2019-03-31 | −$9.2M | −$3.5M | — | — |
| Q4 2018 | 2018-12-31 | −$9.2M | $377,676 | — | — |
| Q3 2018 | 2018-09-30 | −$8.1M | −$7.5M | — | — |
| Q2 2018 | 2018-06-30 | −$8.6M | −$5.4M | — | — |
| Q1 2018 · Mar 31 | 2018-03-31 | −$5.8M | −$2.9M | — | — |
| Q4 2017 | 2017-12-31 | −$9.5M | −$8.8M | — | — |
| Q1 2018 · Sep 30 | 2017-09-30 | −$634,324 | $206,655 | — | — |
| Q4 2017 | 2017-06-30 | −$3.2M | −$2.2M | — | — |
| Q3 2017 | 2017-03-31 | −$2.8M | −$1.7M | — | — |
| Q4 2016 | 2016-06-30 | −$714,786 | $1.7M | — | — |
| Q3 2016 | 2016-03-31 | −$840,979 | $616,751 | — | — |
| Q2 2016 | 2015-12-31 | −$988,296 | $581,529 | — | — |
| Q1 2016 | 2015-09-30 | −$1.1M | $881,570 | — | — |
| Q4 2015 | 2015-06-30 | −$2.4M | −$1.2M | — | — |
| Q3 2015 | 2015-03-31 | −$1.5M | $99,739 | — | — |
| Q2 2015 | 2014-12-31 | −$1.6M | −$147,886 | — | — |
| Q1 2015 | 2014-09-30 | −$2.0M | −$1.3M | — | — |
| Q4 2014 | 2014-06-30 | −$1.2M | −$275,126 | — | — |
| Q3 2014 | 2014-03-31 | −$1.6M | $196,960 | — | — |
| Q2 2014 | 2013-12-31 | −$1.4M | −$856,524 | — | — |
| Q1 2014 | 2013-09-30 | −$670,465 | −$32,730 | — | — |
| Q4 2013 | 2013-06-30 | −$946,328 | $33,694 | — | — |
| Q3 2013 | 2013-03-31 | −$1.8M | −$730,883 | — | — |
| Q2 2013 | 2012-12-31 | −$565,415 | $724,687 | — | — |
| Q1 2013 | 2012-09-30 | −$637,735 | $834,440 | — | — |
| Q3 2012 | 2012-03-31 | −$980,022 | $627,623 | — | — |
| Q4 2011 | 2011-06-30 | −$1.0M | — | — | — |
| Q3 2011 | 2011-03-31 | −$1.3M | — | — | — |
| Q2 2011 | 2010-12-31 | −$1.5M | — | — | — |
| Q1 2011 | 2010-09-30 | −$1.6M | — | — | — |
Eloxx Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$1.9M to −$31.9M, a net decrease of $30.0M. Eloxx Pharmaceuticals's latest reported quarter, Q3 2023, generated −$3.5M in free cash flow, an increase of $3.5M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Eloxx Pharmaceuticals filings at SEC.gov ↗